Posted by Michael Wonder on 17 Jul 2020
Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
17 July 2020 - Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the target population.
The situation is complex for non-small-cell lung cancer (NSCLC) due to highly specific therapeutic indications.
The aim of this study was to compare the different methodological steps applied to determine the target population in dossiers on medicines for NSCLC.
